Combination of Sputnik V component with AstraZeneca, Sinopharm and Moderna shows high safety: RDIF study

In a finding that could provide a boost to the global fight against COVID-19, Russian researchers have discovered that a combination of variants of Sputnik V with vaccines of AstraZeneca, Sinopharm, and Moderna could provide immunity against COVID-19. A study by the Russian Direct Investment Fund (RDIF) has said that the approach could provide a longer and more durable immunity against the deadly virus.

“A study was conducted in Argentina, in which, the heterogeneous boosting approach (‘vaccine cocktail’ using human adenovirus serotype 26 as the first component and human adenovirus serotype 5 as the second component) was at the core of Sputnik V, the world’s first registered vaccine against coronavirus. With this approach proving successful in creating a longer and more durable immunity against the coronavirus,” RDIF said in a statement.

According to news agency ANI, 121 volunteers were analysed in the regimens – Sputnik Light/AstraZeneca, Sputnik Light/Moderna, Sputnik Light/Sinopharm, Sputnik Light/Sputnik Light compared to control group Sputnik V 1 Comp./Sputnik V 2 Comp.

Sputnik V is effective against the Delta variant of COVID-19: Study

“RDIF is the first country to offer vaccine cooperation to other producers to conduct joint mix and match studies. This approach is the most promising one to fight the pandemic and new strains of coronavirus emerging around the world,” Kirill Dmitriev, CEO of RDIF said.

The outcome of the study may be important given that it could strengthen the ongoing global fight against the deadly virus. In India, Sputnik is being produced in partnership with the Serum Institute of India, the largest vaccine producer in the world. A recent study has shown that it is one of the most effective vaccines against COVID-19, including its Delta variant.